Is Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

Wei-Wu He Biography and Net Worth

CEO of CASI Pharmaceuticals

Dr. He has been Chairman of the Company since February 2012 and Executive Chairman since February 2018 and Chief Executive Officer since 2019. Prior to joining CASI, Dr. He was the CEO of OriGene Technologies, Inc. and remains Chairman of the Board of Directors. He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established since 2000. Dr. He has been involved in founding or funding over 60 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 30 research publications and inventor of over 32 issued patents. Dr. He received his Ph.D. in Molecular Biology from Baylor College of Medicine and received an M.B.A. degree from the Wharton School.

What is Wei-Wu He's net worth?: The estimated net worth of Wei-Wu He is at least $12.41 million as of March 26th, 2021. Dr. He owns 4,683,994 shares of CASI Pharmaceuticals stock worth more than $12,412,584 as of December 21st. This net worth estimate does not reflect any other investments that Dr. He may own. Additionally, Dr. He receives an annual salary of $565,360.00 as CEO at CASI Pharmaceuticals. Learn More about Wei-Wu He's net worth.
How old is Wei-Wu He?: Dr. He is currently 59 years old. There are 6 older executives and no younger executives at CASI Pharmaceuticals. The oldest executive at CASI Pharmaceuticals is Dr. Alexander A. Zukiwski M.D., Executive VP & Chief Medical Officer, who is 67 years old. Learn More on Wei-Wu He's age.
What is Wei-Wu He's salary?: As the CEO of CASI Pharmaceuticals, Inc., Dr. He earns $565,360.00 per year. The highest earning executive at CASI Pharmaceuticals is Dr. Wei Zhang Ph.D., President, who commands a salary of $1,130,000.00 per year. Learn More on Wei-Wu He's salary.
How do I contact Wei-Wu He?: The corporate mailing address for Dr. He and other CASI Pharmaceuticals executives is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. CASI Pharmaceuticals can also be reached via phone at 861065086063 and via email at [email protected]. Learn More on Wei-Wu He's contact information.
Has Wei-Wu He been buying or selling shares of CASI Pharmaceuticals?: Wei-Wu He has not been actively trading shares of CASI Pharmaceuticals within the last three months. Most recently, on Wednesday, November 17th, Wei-Wu He bought 200,000 shares of CASI Pharmaceuticals stock. The stock was acquired at an average cost of $0.99 per share, with a total value of $198,000.00. Learn More on Wei-Wu He's trading history.

Wei-Wu He Insider Trading History at CASI Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/17/2021	Buy	200,000	$0.99	$198,000.00
3/26/2021	Buy	3,000,000	$2.05	$6,150,000.00	4,683,994
7/22/2020	Buy	2,952,426	$1.90	$5,609,609.40	4,836,523
5/20/2020	Buy	86,265	$2.61	$225,151.65	1,827,663
5/18/2020	Buy	438,932	$2.05	$899,810.60	1,827,663
3/27/2020	Buy	6,880	$2.09	$14,379.20	1,358,900
3/25/2020	Buy	196,398	$1.94	$381,012.12	1,023,925
3/19/2020	Buy	234,488	$1.57	$368,146.16	827,527
3/17/2020	Buy	264,192	$1.50	$396,288.00	827,527
8/16/2019	Buy	20,000	$3.20	$64,000.00	827,527
8/14/2019	Buy	160,000	$3.17	$507,200.00	807,527
3/19/2018	Buy	3,086,419	$3.24	$9,999,997.56	847,527
10/10/2017	Buy	100,000	$1.95	$195,000.00
10/6/2017	Buy	200,000	$1.83	$366,000.00
9/19/2017	Buy	207,502	$1.75	$363,128.50	513,525
9/18/2017	Buy	173,500	$1.75	$303,625.00	513,525
9/15/2017	Buy	315,327	$1.33	$419,384.91	212,323
10/3/2016	Buy	1,871,605	$1.19	$2,227,209.95	24,698

Wei-Wu He Buying and Selling Activity at CASI Pharmaceuticals

CASI Pharmaceuticals Company Overview

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Today's Range

Now: $2.65

$2.65

$2.82

50 Day Range

MA: $4.82

$2.69

$6.14

2 Week Range

Now: $2.65

$2.05

$8.19

Volume

76,852 shs

Average Volume

130,968 shs

Market Capitalization

$40.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Is Starlink Set For The Largest IPO In History?

From Paradigm Press | Ad

Click here now for the urgent details.